Prostate Cancer Clinical Trial
Official title:
A Phase II, Multi-center, Single-arm, Prospective Study of Darolutamide + ADT Prior to Radical Prostatectomy (RP) in High-risk/Very High-risk Localized Prostate Cancer
NCT number | NCT06029036 |
Other study ID # | 22440 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | August 5, 2023 |
Est. completion date | July 31, 2026 |
Scientific Rationale: High risk localized prostate cancer (PCa) is associated with higher rates of biochemical recurrence, clinical recurrence, metastasis and PCa-specific death. Novel hormone therapies(NHT) have shown a significant survival advantage with respect to classical ADT in later stages of PCa and have already been investigated in neoadjuvant setting. PURPOSE: To assess antitumor effect by measuring pathological tumor volume with pathological downstaging following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for high-risk localized prostate cancer patients.
Status | Recruiting |
Enrollment | 53 |
Est. completion date | July 31, 2026 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male =18 years of age. 2. Able to Sign informed consent form independently. 3. Non-metastatic adenocarcinoma of the prostate. 4. Subjects must have as least one of the following features according to NCCN definition of high-risk: Gleason score =8, or PSA >20ng/ml,or=clinical T3a. 5. Subjects with pelvic lymph node involvement(N1) can be included. 6. Candidate for radical prostatectomy with or without pelvic lymph node dissection as per the investigator. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 8. Subjects must have normal organ and marrow function as defined below: Hemoglobin = 9.0 g/dL;Absolute neutrophil count (ANC) = 1,500/mcL; Platelets = 100,000/mcL, independent of transfusions/growth factors within 3 months of treatment start; Serum potassium = 3.5 mmol/L; Serum total bilirubin = 2.0 x upper limit of normal (ULN) (except in subjects with Gilbert's syndrome who have a total bilirubin > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is = 1.5 x ULN, subject may be eligible);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 2.5 x ULN;Serum albumin = 3.0 g/dL;Serum creatinine < 2.0 x ULN. Exclusion Criteria: 1. Prostate cancer with neuroendocrine differentiation or small cell features 2. Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. 3. History of prior systemic or local therapy for prostate cancer, including pelvic radiation for prostate cancer. 4. Subjects who are planning bilateral orchidectomy during the treatment period of the study. 5. Intolerable with darolutamide or ADT treatment. 6. Candidates of other clinical trials. 7. Any prior malignancy within 5 years. 8. Complications include significant cardiovascular disease, active infection, astrointestinal disorders, or any other complications that in the opinion of the investigator. 9. Any condition that in the opinion of the investigator would preclude participation in this study. |
Country | Name | City | State |
---|---|---|---|
China | Peking University First Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University First Hospital | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Xijing Hospital of Air Force Military Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of pathological downstaging | Percentage of patients with tumor downstaging | 6 months | |
Secondary | pCR or MRD | Pathologic complete response or Minimal Residual Disease(defined as overall diameter <5 mm) | 6 months | |
Secondary | PSM | Percentage of patients with positive surgical margins | 6 months | |
Secondary | Rate of peri-operative complications | including delay in surgery, intra-operative complications, and postoperative complications | within 30 days of surgery | |
Secondary | Biochemical complete response | PSA <0.1ng/ml prior to RP | 6 months | |
Secondary | PSA undetectable rate | PSA<0.02 ng/ml | 12 months post-RP | |
Secondary | 2-year biochemical progression-free survival, bPFS | PSA>0.2 ng/ml | 24 months post-RP | |
Secondary | AEs/SAEs | The level of AEs defined by NCI-CTCAE v5.0. Safety assessments will be assessed and documented after initiation of study drug, regardless of relationship to study drug. | Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |